A recent study highlights bispecific antibodies #BsAbs as a powerful bridging therapy before BCMA CAR-T cell treatment for relapsed/refractory multiple myeloma #RRMM

@theaacr.bsky.social #bcd_aacr

#Onco404 #Cancer #Kanser #MultipleMyeloma #CARTCellTherapy #MedSky #Immunotherapy #Hematology